EVE Health to acquire Nextract entering into $5.3bn erectile dysfunction market
EVE Completes Nextract Acquisition SYDNEY: EVE Health Group (ASX: EVE) announced Monday it has agreed to acquire Australian biotech firm Nextract Pty Ltd, marking its entry into the $5.3 billion global erectile dysfunction market. The deal, valued at $3 million…